Catalog makes Hartwig Medical Database easily searchable
Hartwig Medical Foundation maintains a catalog of the Hartwig Medical Database with whole-genome data on full tumor genomes: https://catalog.hartwigmedicalfoundation.nl. The database currently contains data on over 5,800 patients, including treatment and response data. In addition, this database contains RNA sequencing data from more than half of the patients.
Hartwig Medical Foundation’s mission is to provide the best possible care for today’s patient as well as the patient of tomorrow. An important part of this is making genomic and relevant clinical data available to research groups, with consent from the patients involved. The public catalog of Hartwig Medical Database makes it easy to gain insight into the available data, enabeling a quick and easy overview if there are tumor genomes in the database of interest to the researcher.
The catalog is interactive and the database can be viewed through flexible visualizations of different data types in multiple dimensions. Filtering is possible per data type, e.g. tumor type, biopsy location, age, gender, treatment given, treatment outcome and RNA availability.
This is the world’s largest publicly available dataset of its kind. It is available free of charge for research to improve the care for cancer patients of today and tomorrow. Hartwig Medical Foundation is grateful for the cooperation of so many patients, they have chosen to share their data for the benefit of science and other patients.
For the conditions and procedures for requesting access to the data, please visit our website.
Hartwig Medical Foundation collects data in collaboration with the CPCT, the Netherlands Cancer Institute and more than 40 Dutch hospitals with the consent of patients in various studies.
This unique source is continuously growing with increasing adaptation of complete genome diagnostics in regular healthcare in the Netherlands. Cancer of unknown primary origin is the first indication with a reimbursement title for this test and shows clearly the added value for patients in daily practice.
All news
Also read
Hartwig tools now available as a nextflow nf-core pipeline called oncoanalyser
The University of Melbourne Centre for Cancer Research (UMCCR) Genomics Platform Group, led by Professor Oliver Hofmann, has collaborated with …
Predicting therapy success based on gene expression
In addition to Whole Genome Sequencing of DNA, Hartwig Medical Foundation performs Whole Transcriptome Sequencing of RNA. Researcher Marjolein Lansbergen …
The starting point – always the patient
Frank van Wijck, science journalist Ele Visser is handing over his position as chairman of Hartwig Medical Foundation’s Data Access Board …
We want to extract the maximum amount of information from the patient’s tumor. This DNA test is the The complete DNA test is the best available tool to extract the maximum amount of information from the patient’s tumor. We only need one tissue sample with sufficient tumor cells. We literally analyze the entire genome, including parts of the DNA that show mutations of which we don’t yet know the importance. This test is tumor-independent and future-proof. These are the two most important advantages of WGS.